Octodrine

Octodrine
Clinical data
Other namesDimethylhexylamine; DMHA; Ottodrina; Vaporpac; Amidrine; 2-Aminoisooctane; 2-Amino-6-methylheptane; 1,5-Dimethylhexylamine; 6-Methyl-2-heptylamine; 6-Methyl-2-heptanamine; Isoctaminium; SKF-51; SK&F-51; NSC-759813
Routes of
administration
Oral, inhaled
ATC code
  • none
Legal status
Legal status
Pharmacokinetic data
MetabolismHydroxylation
MetabolitesHeptaminol
Identifiers
  • 6-methylheptan-2-amine
CAS Number
PubChem CID
DrugBank
ChemSpider
UNII
CompTox Dashboard (EPA)
ECHA InfoCard100.008.047
Chemical and physical data
FormulaC8H19N
Molar mass129.247 g·mol−1
3D model (JSmol)
  • CC(C)CCCC(C)N
  • InChI=1S/C8H19N/c1-7(2)5-4-6-8(3)9/h7-8H,4-6,9H2,1-3H3
  • Key:QNIVIMYXGGFTAK-UHFFFAOYSA-N
  (verify)

Octodrine, also known as dimethylhexylamine (DMHA) and sold under the brand name Vaporpac among others, is a sympathomimetic and stimulant medication that was formerly used in the treatment of hypotension (low blood pressure).

It has been studied in a dozen animal studies from the 1940s through the 1970s. These studies found that octodrine can increase blood pressure and cardiac output in animals. The drug was previously approved for use by the Food and Drug Administration (FDA) as an inhalant (i.e., Vaporpac and Tickle Tackle Inhaler) and in Germany as an oral medication as part of a multi-component medication (i.e., Ambredin and Ordinal), but is no longer available.

DMHA has also been found as an adulterant in sports supplements and is sold online as a designer drug. The presence of a reductive amination byproduct confirms its synthetic origin.

In the United States, the FDA considers DMHA to be an unsafe ingredient in dietary supplements. In 2019, the FDA issued nine warning letters to US manufacturers of dietary supplements containing DMHA as an unsafe food additive, deeming such products to be adulterated and illegal for marketing.